<DOC>
	<DOC>NCT01283503</DOC>
	<brief_summary>In this study, BKM120 will be administered to adult patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists. The trial will confirm the safety and tolerability and determine the maximum tolerated dose (MTD) of BKM120 in Japanese patients.</brief_summary>
	<brief_title>A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1. Patients with histologically confirmed, advanced unresectable solid tumors who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists. 2. At least one measurable or nonmeasurable lesion as defined by RECIST guidelines for solid tumors. 3. Age ≥ 20 years 4. Eastern Cooperative Oncology Group Performance Status (ECOG P.S.) of ≤ 2 5. Life expectancy of ≥ 12 weeks 6. Patients must have the laboratory values 1. Patients with a history of primary central nervous system tumors or brain metastases or who have signs/symptoms attribute to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases 2. Prior treatment with a PI3K inhibitor 3. Patients with any peripheral neuropathy ≥ CTCAE grade 2 4. Patients with unresolved diarrhea ≥ CTCAE grade 2 5. Women of childbearing potential who are pregnant or breast feeding. Men or women of reproductive potential not to sign informed consent for birth control. Barrier contraceptives must be used throughout the trial and six months after the end of treatment. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>PI3K,</keyword>
	<keyword>Advanced solid tumor</keyword>
</DOC>